Merck & Co Inc recalls Liptruzet (ezetimibe and atorvastin) tablets,10 mg/80 mg, a) 30 count blister (NDC 66582-323-30), b) 90 count blister

Recalled May 14, 2014 · FDA recall D-1312-2014 · Merck &

Hazard

Defective Container; some of the outer laminate foil pouches allowed in air and moisture, which could potentially decrease the effectiveness or change the characteristics of the product. · FDA Class III

Units

11,462 cartons

Sold at

Nationwide and Puerto Rico

Description

Defective Container; some of the outer laminate foil pouches allowed in air and moisture, which could potentially decrease the effectiveness or change the characteristics of the product.

Product

Liptruzet (ezetimibe and atorvastin) tablets,10 mg/80 mg, a) 30 count blister (NDC 66582-323-30), b) 90 count blister (NDC 66582-323-54), Rx only, Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc, Whitehouse Station, NJ 08889

Manufacturer(s)

Merck & Co Inc

Source: U.S. Food and Drug Administration. Official recall notice on fda.gov →